WINTERMUTE BIOMEDICAL RECEIVES ETHICS APPROVAL FOR PHASE IB CLINICAL TRIAL OF SOLEXAN IN SHINGLES PATIENTS
Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials … Wintermute Biomedical is excited to report that in December 2023 they have received full approval to conduct a Phase IB clinical trial in Australia using their first-in-class topical antiviral, Solexan. Solexan has been developed over the last 12 years by Wintermute Biomedical as a […]
Continue Reading